Please assess the completion status of the following clinical trial:

Trial Title: Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed Informed Consent form.~2. Males and females 18 to 65 years of age (inclusively).~3. Patients with chronic hepatitis B (HBeAg-positive or negative) and HBsAg-positive for at least 6 months prior to Screening.~4. Positive for anti-HDV antibodies for at least 6 months prior to Screening.~5. HDV RNA-positive at Screening.~6. ALT ≥ 1 x ULN and \< 10 x ULN.~7. The patient agreed to use adequate method of contraception during the study, starting from the time of Informed Consent signing and until completion of the Follow-up Period.~Exclusion Criteria:~1. Intolerance or hypersensitivity to the active ingredient or other components of the study drug Myrcludex B.~2. Intolerance or hypersensitivity to interferons alfa, genetically engineered E.coli medications, polyethylene glycol or other components of peginterferon alfa-2a.~3. Previous treatment with Myrcludex B (patients with previous exposure to interferon are eligible).~4. Therapy with antiviral drugs for chronic viral hepatitis B with delta-agent over the previous 6 months.~5. Therapy with anti-tumour agents (including radiotherapy) or immunomodulatory medications (including systemic glucocorticoids) over the previous 6 months.~6. The following laboratory test results at Screening:~   1. Hemoglobin \< 100 g/L~  2. Leucocytes \< 3000/µL~  3. Neutrophils \< 1500/µL~  4. Platelets \< 90000/µL~  5. Serum creatinine \>1.5 x ULN.~7. Total bilirubin \> 34.2 µM/L. Patients with higher total bilirubin may be enrolled upon consultation with the study Medical Monitor, if there is clear evidence that the elevated bilirubin is caused by Gilbert's syndrome.~8. Current or previous decompensated liver disease, including coagulopathy, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminaemia, ascites, and oesophageal varices haemorrhage; Child-Pugh score of B/C or ≥6 points.~9. HCV or HIV coinfection (patients with anti-HCV antibodies and no HCV RNA at Screening are eligible).~10. Hepatocellular carcinoma.~11. Signs of drug- or alcohol-induced liver disease or any other medical conditions associated with chronic liver disease (e.g. autoimmune hepatitis, hemochromatosis, thalassaemia, alcoholic hepatitis, toxic liver disease).~12. Contraindications for liver biopsy.~13. Concurrent malignancy (current diagnosed or suspected malignancy; risk of a previous malignancy recurrence).~14. Severe decompensated cardiovascular diseases, including unstable and poorly controlled conditions, over 6 months before Screening.~15. History of poorly controlled thyroid conditions or clinically significant signs of thyroid dysfunction at Screening.~16. Previous or current severe renal failure or significant renal dysfunction at Screening.~17. Previous or current chronic pulmonary disease with respiratory distortion at Screening.~18. Previous or current severe retinopathy, significant ophthalmology disorders associated with diabetes mellitus or hypertension.~19. Previous or current severe psychiatric disorders at Screening (e.g. severe depressions, suicidal attempts, severe neuroses or cognitive disorders).~20. Previous or current endocrine disorders (hypoglycaemia, hyperglycaemia, diabetes mellitus) that are not adequately controlled at Screening.~21. History of visceral organ transplantation.~22. Signs of drug and/or alcohol dependence (80 g of alcohol/day for men and 40 g of alcohol/day for women) within 1 year before Screening.~23. History of immune disorders (e.g. idiopathic thrombocytopenic purpura, lupus erythematosus, sclerodermia, severe psoriasis, rheumatoid arthritis).~24. Need for concomitant use of glucocorticoids or myelotoxic agents.~25. Participation in another clinical study within 30 days prior to enrollment into this study.~26. Pregnant or breast-feeding females.~27. Any other condition that, in the opinion of Investigator, precludes the patient from taking part in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): PEG IFN alfa-2a 180 µg for 48 weeks
- Arm B (Type: EXPERIMENTAL): Myrcludex B 2 mg + PEG IFN alfa-2a 180 µg for 48 weeks
- Arm C (Type: EXPERIMENTAL): Myrcludex B 5 mg + PEG IFN alfa-2a 180 µg for 48 weeks
- Arm D (Type: EXPERIMENTAL): Myrcludex B 2 mg for 48 weeks
- Arm E (Type: EXPERIMENTAL): Myrcludex B 10 mg (10 mg once a day) + PEG-IFN alfa-2a 180 μg during 48 weeks
- Arm F (Type: EXPERIMENTAL): Myrcludex B 10 mg (5 mg twice a day) + Tenofovir during 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).